Product information
From Health Canada
Note - The product information found within this database originates from organizations not subject to the Official Languages Act and is available in the language in which it was written and submitted to Health Canada.
Note - The market status of a product is now available in the LNHPD and identifies if a product is "marketed" or "not marketed" in Canada. Product licence holders may voluntarily provide the Natural and Non-Prescription Health Products Directorate (NNHPD) with information about whether their product is currently available to Canadian consumers. Where no information has been provided, the default status is "not marketed". The "current status" field remains unaffected and will continue to indicate the status of the product licence (i.e., active, discontinued, stop sale, cancelled, or suspended). Note that where a licence has been suspended, cancelled or under stop sale, the product cannot be legally sold in Canada.
Product licence holders - if you wish to update a product's market status, you are invited to complete the Natural Health Products Market Notification Web Form. As with all other notifications, there is no current service standard. The NNHPD will process the market status update as soon as feasible, based on its available resources. As a reminder, market notification is voluntary; therefore, a licence holder is not required to wait for the LNHPD to be updated before a licensed product is sold in Canada. As such, products that are identified in the LNHPD as "not marketed" may still be sold in Canada.
- Natural Product Number (NPN):
- 80079406
- Market status:
- Marketed
- Licence Status:
- Active
- Brand name(s):
-
NutraSea® Dry Eye Targeted Omega-3
;
NutraSea Dry Eye ;
NutraSea Dry Eye Softgels ;
NutraSea Dry Eye Targeted Omega-3 Softgels ;
NutraSea Targeted Dry Eye - Licence holder:
- Nature's Way of Canada Ltd.
- Dosage Form:
- Capsule, soft
- Recommended route of administration:
-
Oral
Sub population (Sub Pop.) | Quantity (Qty) | Frequency (Freq.) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sub Pop. | Age | Min. | Max. | UoM Footnote1 Age | Qty | Min. | Max. | UoM Qty | Freq. | Min. | Max. | UoM Freq. |
Adults and Adolescents | 14 | year(s) | 2.0 | capsule | 2 | Day(s) | ||||||
- Recommended use or purpose:
- Source of omega-3 fatty acids for the maintenance of good health. Helps support cognitive health and/or brain function. Helps relieve symptoms of Dry Eye Syndrome. Helps improve symptoms of Dry Eye Syndrome. Helps provide relief/improve symptoms of dry eye syndrome including support for proper tear function (decreased rate of tear evaporation and increase in tear secretion). Helps support proper tear function in persons with Dry Eye Syndrome. Helps decrease the rate of tear evaporation in persons with Dry Eye Syndrome. Helps increase tear secretion in persons with Dry Eye Syndrome. Source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health.
- Risk Information:
- Cautions and Warnings
- If symptoms of dry eyes worsen, consult a health care practitioner.
Medicinal ingredients | Quantity (Qty) | Extract | Potency |
---|---|---|---|
Borago officinalis |
145.4 milligrams
|
24.5
milligrams
Gamma-Linolenic acid |
|
Fish oil |
0.7 Grams
|
300.0
milligrams
Eicosapentaenoic acid 75.0 milligrams Docosahexaenoic acid |
|
Oenothera biennis |
145.4 milligrams
|
13.0
milligrams
Gamma-Linolenic acid |
- List of non-medicinal ingredients:
-
- Gelatin
- Glycerin
- Mint Flavour
- Purified water
- Rosmarinus Officinalis (Rosemary) Leaf Extract
- Tocopherols
- Date of licensing:
- 2017-08-10
- Revised date of licence:
- 2024-12-24
Application information
Related information
Contact us
For technical support or if you have general questions concerning the content of this database, please contact the Natural Health Products Directorate (NHPD).